SD Biosensor Inc (137310) - Total Assets
Based on the latest financial reports, SD Biosensor Inc (137310) holds total assets worth ₩3.98 Trillion KRW (≈ $2.70 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check cash flow reinvestment rate of SD Biosensor Inc to assess the company's total reinvestment commitment from operating cash flow.
SD Biosensor Inc - Total Assets Trend (2019–2024)
This chart illustrates how SD Biosensor Inc's total assets have evolved over time, based on quarterly financial data. Check cash flow quality index of SD Biosensor Inc to evaluate the quality of earnings relative to operating cash generation.
SD Biosensor Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
SD Biosensor Inc's total assets of ₩3.98 Trillion consist of 24.1% current assets and 75.9% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 4.6% |
| Accounts Receivable | ₩136.41 Billion | 3.5% |
| Inventory | ₩232.17 Billion | 6.0% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩723.12 Billion | 18.6% |
| Goodwill | ₩1.37 Trillion | 35.3% |
Asset Composition Trend (2019–2024)
This chart illustrates how SD Biosensor Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of SD Biosensor Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SD Biosensor Inc's current assets represent 24.1% of total assets in 2024, a decrease from 63.4% in 2019.
- Cash Position: Cash and equivalents constituted 4.6% of total assets in 2024, down from 11.3% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 53.0% of total assets, an increase from 2.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 35.3% of total assets.
SD Biosensor Inc Competitors by Total Assets
Key competitors of SD Biosensor Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087
|
China | CN¥12.68 Billion |
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥29.91 Billion |
|
Pegavision
TW:6491
|
Taiwan | NT$16.17 Billion |
|
Tarsons Products Limited
NSE:TARSONS
|
India | Rs11.64 Billion |
|
SciVision Biotech Inc
TW:1786
|
Taiwan | NT$2.67 Billion |
|
Nyxoah
BR:NYXH
|
Belgium | €93.60 Million |
|
I.Ceram SA
PA:ALICR
|
France | €3.91 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.33 Billion |
SD Biosensor Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.50 | 5.83 | 1.87 |
| Quick Ratio | 5.98 | 4.52 | 1.34 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩1.06 Trillion | ₩768.84 Billion | ₩599.86 Billion |
SD Biosensor Inc - Advanced Valuation Insights
This section examines the relationship between SD Biosensor Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.34 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 2.6% |
| Total Assets | ₩3.89 Trillion |
| Market Capitalization | $564.21 Million USD |
Valuation Analysis
Below Book Valuation: The market values SD Biosensor Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: SD Biosensor Inc's assets grew by 2.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for SD Biosensor Inc (2019–2024)
The table below shows the annual total assets of SD Biosensor Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩3.89 Trillion ≈ $2.64 Billion |
+2.63% |
| 2023-12-31 | ₩3.79 Trillion ≈ $2.57 Billion |
+16.15% |
| 2022-12-31 | ₩3.26 Trillion ≈ $2.21 Billion |
+8.55% |
| 2021-12-31 | ₩3.01 Trillion ≈ $2.04 Billion |
+105.60% |
| 2020-12-31 | ₩1.46 Trillion ≈ $990.54 Million |
+761.22% |
| 2019-12-31 | ₩169.72 Billion ≈ $115.02 Million |
-- |
About SD Biosensor Inc
SD Biosensor, Inc., together with its subsidiaries, operates as an in-vitro diagnostic company in South Korea, India, Asia, Europe, the Americas, and Africa. The company offers STANDARD Q, which provides rapid diagnostic products; STANDARD F, a fluorescence immunodiagnostic system for various qualitative and quantitative diagnosis items; STANDARD E, an enzyme immunoassay diagnosis for large-volum… Read more